{"id":"NCT01838876","sponsor":"Forest Laboratories","briefTitle":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","officialTitle":"A Phase 3, Long-term, Open-label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-29","primaryCompletion":"2015-07-27","completion":"2015-07-27","firstPosted":"2013-04-24","resultsPosted":"2019-08-21","lastUpdate":"2019-08-21"},"enrollment":442,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Cariprazine","otherNames":[]},{"type":"DRUG","name":"Antidepressant Therapy (ADT)","otherNames":[]}],"arms":[{"label":"Cariprazine + ADT","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period","timeFrame":"First dose of study drug to last dose of study drug in the 26-week Treatment Period and within 30 days of last dose of study drug for participants who did not participate in the 2-week Safety Follow-up Period (Up to 30 weeks)","effectByArm":[{"arm":"Cariprazine + ADT","deltaMin":274,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":90,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":345},"commonTop":["Akathisia","Headache","Weight increased","Anxiety","Insomnia"]}}